Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Sands

Urology Charlottesville, VA Medical Doctor

NPI 1861804098 CMS profile 701450

500 Ray C Hunt Dr, Charlottesville, VA 22903

Open in the dashboard

General payments

$6,035

91 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Sands of Charlottesville, VA is reported in the CMS Open Payments database as having received $6,035 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,567 12
2024 General $341 6
2023 General $932 19
2022 General $1,876 26
2021 General $448 13
2020 General $86 5
2019 General $786 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Sands
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Kenneth Sands were reported at $1,567. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Kenneth Sands Urology median Middle half National median
2019 $786 $480 $147–$1,201 $163
2020 $86 $246 $87–$645 $114
2021 $448 $358 $111–$1,000 $132
2022 $1,876 $476 $143–$1,263 $149
2023 $932 $560 $168–$1,461 $160
2024 $341 $563 $170–$1,464 $164
2025 $1,567 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,770 52 payments
  2. Intuitive Surgical, Inc. $1,450 6 payments
  3. KARL STORZ Endoscopy-America $827 10 payments
  4. Baxter Healthcare $467 5 payments
  5. NeoTract Inc. $250 3 payments
  6. Ambu Inc. $78 2 payments
  7. 180 Medical, Inc. $49 2 payments
  8. Teleflex LLC $43 2 payments
  9. Tolmar, Inc. $34 2 payments
  10. PROCEPT BioRobotics Corporation $25 1 payment
  11. Other $42 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,591 81 payments
  2. Travel and Lodging $1,437 6 payments
  3. Education $7 4 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $1,450 6 payments
  2. General - Kidney Stone Disease $1,102 8 payments
  3. AMS $544 7 payments
  4. LITHOCLAST $352 12 payments
  5. Flex-X $255 2 payments
  6. UROLIFT $250 3 payments
  7. LithoVue $244 3 payments
  8. TISSEEL Surgical Care $236 3 payments
  9. TISSEEL Surgical Care $231 2 payments
  10. General - Erectile Dysfunction $158 5 payments
  11. Other $921 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

204

Median for Urology: 1,053

Drug cost

$10,154

Median for Urology: $101,464

Branded share of claims

10.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 11 $6,559
Tamsulosin Hcl Generic 82 $1,269
Potassium Citrate Er Potassium Citrate Brand 11 $1,192
Finasteride Generic 29 $487
Trospium Chloride Generic 12 $458
Cephalexin Generic 19 $86
Levofloxacin Generic 17 $61
Oxycodone Hcl Generic 23 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$90,989

Medicare's payments for the services billed

Medicare patients

394

Average age 74

Services billed

938

137 women, 257 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Chronic kidney disease 38%
Ischemic heart disease 30%
Diabetes 29%
Atrial fibrillation 25%
Cancer 22%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record